Dr. Carl H. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and the director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania.
Dr. June is renowned for his groundbreaking work in the development of the successful chimeric antigen receptor (CAR) T cell therapy, which uses genetically modified anti-cancer T cells to eliminate cancer cells. In recognition of his contributions, he was awarded the 2012 William B. Coley Award and earned membership in the American Association of Physicians. He continues to investigate and optimize CAR T cell therapy, to make it more effective not only for blood cancers, but also to help patients with other types of cancer.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. June is a member of CRI’s Clinical Leadership Committee.
We’ve come to the tipping point now where there is acceptance that immunotherapy can provide a long-lasting effect and has a lot of promise. There’s always been that promise, but now it’s going to be realized.
Let's spread the word about Immunotherapy! Click to share this page with your community.